Salt Lake City, UT (PRWEB) May 01, 2014
Catheter Connections, a leading developer of medical devices for the prevention of IV catheter-related bloodstream infections, announced today that the United States District Court for the Southern District of California has ruled that all patent claims asserted by Ivera against Catheter Connections’ DualCap Solo™ are invalid. The Court’s ruling is the final judgment in the case and is in accord with the recent actions of the US Patent and Trademark Office (PTO) rejecting the asserted patent claims in Rights of Appeal Notices issued in inter partes reexamination proceedings. Ivera Medical Corporation v. Catheter Connections, Inc., Case Number: 3:12-cv-00954-H-RBB.
“Based upon past behavior, it is possible Ivera will seek to appeal the Court’s ruling, but given the Court’s careful analysis and the PTO’s consistent position we are confident that the outcome will be the same,” said Guy J. Jordan, PhD, Chairman and CEO of Catheter Connections. “IV catheter related bloodstream infections are costly and deadly, and the DualCap System™ can help hospitals protect patients from the contamination that causes these infections. With our DualCap® technology, we are eager to continue our focus on saving lives.”
About Catheter Connections®
Headquartered in Salt Lake City, Utah, Catheter Connections, Inc., develops and commercializes innovative vascular access products designed to protect patients from acquiring infections during intravenous infusion therapy. Its DualCap System™ is a family of user-friendly products that provides healthcare facilities with a cost-effective, integrated solution for IV disinfection and protection, helping in the fight against IV catheter-related blood stream infections. Designed by nurses for nurses, flagship product DualCap® safely disinfects both IV tubing end connectors and IV catheter access valves — a major breakthrough for infection control. For more information, visit http://www.catheterconnections.com.